Il-6 Is Non-Essential to Murine CD19 CAR Efficacy, but Can Mediate Acute GVHD Following Allogeneic BMT With CAR T Cell Infusion

Journal for ImmunoTherapy of Cancer - United Kingdom
doi 10.1186/2051-1426-3-s2-p226
Full Text
Abstract

Available in full text

Date
Authors
Publisher

BMJ

Related search

Toxicities of CD19 CAR-T Cell Immunotherapy

American Journal of Hematology
Hematology
2019English

Allogeneic CAR T Cell Therapies for Leukemia - R1

American Journal of Hematology
Hematology
2019English

Outcomes of Patients With Large B‐Cell Lymphomas and Progressive Disease Following CD19‐Specific CAR T‐Cell Therapy

American Journal of Hematology
Hematology
2019English

Safety of Allogeneic Hematopoietic Cell Transplant in Adults After Cd19 Targeted Chimeric Antigen Receptor-Modified T-Cell (Car-T) Therapy

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Efficacy and Safety of Humanized Anti-Cd19-Car-T Therapy Following Intensive Lymphodepleting Chemotherapy for Refractory/Relapsed B Acute Lymphoblastic Leukaemia

British Journal of Haematology
Hematology
2020English

CAR-T Cells Beyond CD19, UnCAR-Ted Territory

American Journal of Hematology
Hematology
2019English

Cd19/Cd20-Redirected Bispecific Car T Cell Treatment in Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

T-Rapa6 and T-Rapa12 Cells Differentially Mediate Acute GVHD After Low-Intensity Allogeneic HCT

Biology of Blood and Marrow Transplantation
TransplantationHematology
2014English

CAR-T Cells and Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia

Immunotherapy
OncologyAllergyImmunology
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy